Tinodasertib

N/A

Report date: 2025/02/13 13:51:58
NME

Base Information

Drug NameTinodasertib
Drug Alias NameETC-206AUM-001ETC-1907206
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsMAP kinase-interacting serine/threonine-protein kinase 2 inhibitorsMAP kinase-interacting serine/threonine-protein kinase MNK1 inhibitors
TargetsBcr-Abl tyrosine kinaseMAP kinase-interacting serine/threonine-protein kinase 2MAP kinase-interacting serine/threonine-protein kinase MNK1
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesExperimental Therapeutics CentreAgency For Science, Technology And Research
China Registration ClassN/A

Develop Information

Active CompaniesAUM Biosciences Pte LtdHengyi Biomedical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A